News
Fiorentina are set to win the race to sign Inter Milan striker Sebastiano Esposito ahead of Cagliari and Hellas Verona.This ...
Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...
Merck (MRK) is spending about $10 billion to acquire Verona Pharma (VRNA) as the company looks to fill future revenue gaps.
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.
Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma ...
Inter Milan could sign defender Koni De Winter from Genoa this summer on one of two possible conditions.Today’s print edition ...
Fintel reports that on July 9, 2025, Jefferies downgraded their outlook for Verona Pharma plc - Depositary Receipt () ...
Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...
Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Stocks Going Wild. Verona Pharma surged by 20.62 percent on Wednesday to end ...
Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.
21hon MSN
Find insight on Merck, RxSight, and more in the latest Market Talks covering Health Care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results